Clinical trial MS201924-0022
An open-label, multicenter, phase 1b/2a study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the ATR inhibitor M1774 in combination wit cemiplimab in participants with non-squamous non-small cell lung cancer that has progressed on prior anti-PD-(L)1 and platinum-based therapies
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1b |
| Academic trial | Non |
| Sponsor | Merck |
| EudraCT Identifier | 2022-502010-85-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05882734 |
| Last update |